Objective
Annual influenza epidemic and pandemic outbreaks of influenza cause a significant disease burden and mortality in man and have high economical impact in the EU. The major drawbacks of influenza vaccines are their limited efficacy and production methods that are hard to adapt to requirements of continuously changing influenza viruses. We aim to improve the efficacy and production methods of epidemic and pandemic influenza vaccines through
1) Improving epidemic vaccine strain selection based on retrospective and prospective analyses.
2) Improving vaccine strain selection and reference reagents for pandemic influenza.
3) Implementation of reverse genetics technologies to increase flexibility and yield of influenza vaccines.
4) Use of a cell substrate for vaccine production.
5) Use of novel antigen delivery systems.
6) Detailed examination of correlates of protection. Promising strategies will be tested in appropriate animal models.
Fields of science
- social sciencessociologydemographymortality
- natural sciencesbiological sciencesmicrobiologyvirology
- medical and health scienceshealth sciencespublic healthepidemiologypandemics
- medical and health scienceshealth sciencesinfectious diseasesRNA virusesinfluenza
- medical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugsvaccines
Call for proposal
Data not availableFunding Scheme
CSC - Cost-sharing contractsCoordinator
3015 GE ROTTERDAM
Netherlands